TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33336372

Group type: EXPERIMENTAL
Intervention: Curative conventional therapy (radiotherapy)
Number of subjects: 22
Study: 33336538

Group type: EXPERIMENTAL
Intervention: Cervical fluid DNAH5 levels in ectopic pregnancy group
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Cervical fluid CK levels in ectopic pregnancy group
Number of subjects: 85

Group type: COMPARATOR
Intervention: Cervical fluid DNAH5 levels in non-pregnant patients
Number of subjects: 85
Study: 33336642

Group type: EXPERIMENTAL
Intervention: Pregestational BMI increase of 5 kg/m2
Number of subjects: 2791

Group type: EXPERIMENTAL
Intervention: Pregestational BMI increase of 5 kg/m2 in children born to smoker mothers
Number of subjects: 2791

Group type: EXPERIMENTAL
Intervention: Pregestational BMI increase of 5 kg/m2 in children born to non-smoker mothers
Number of subjects: 2791
Study: 33337539

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (apixaban and rivaroxaban)
Number of subjects: 15678

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 15678

Group type: EXPERIMENTAL
Intervention: LMWH
Number of subjects: 15678

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 15678

Group type: COMPARATOR
Intervention: Antithrombin
Number of subjects: 15678
Study: 33337584

Group type: EXPERIMENTAL
Intervention: Manual expert segmentation
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Automated radiographic OA-based model segmentation
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Automated HRC-based model segmentation
Number of subjects: 394

Group type: COMPARATOR
Intervention: Progressor cohort vs non-progressor cohort (manual segmentation)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Progressor cohort vs non-progressor cohort (automated radiographic OA model)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Progressor cohort vs non-progressor cohort (automated HRC model)
Number of subjects: 394
Study: 33337808

Group type: EXPERIMENTAL
Intervention: Personalized exercise plans
Number of subjects: 170
Study: 33337811

Group type: EXPERIMENTAL
Intervention: Biologic therapy in nonelderly patients
Number of subjects: 682

Group type: COMPARATOR
Intervention: Biologic therapy in elderly patients
Number of subjects: 682

Group type: COMPARATOR
Intervention: Biologic withdrawal due to adverse events in elderly patients
Number of subjects: 682

Group type: COMPARATOR
Intervention: Biologic withdrawal due to patient refusal in elderly patients
Number of subjects: 682
Study: 33337937

Group type: EXPERIMENTAL
Intervention: Laser-assisted frenectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional frenectomy methods
Number of subjects: 0
Study: 33338986

Group type: EXPERIMENTAL
Intervention: ACT Out! Social Issue Theater intervention
Number of subjects: 1571

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 1571
Study: 33339120

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic Acid (EPA) treatment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid (DHA) treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: EPA vs DHA
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 24
Study: 33339464

Group type: EXPERIMENTAL
Intervention: Children preparing to transition to oral feeding (CwTF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Children with chronic illnesses
Number of subjects: 0
Study: 33339512

Group type: EXPERIMENTAL
Intervention: Co-Work-Care model including person-centered dialogue meeting and increased collaboration
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Person-centered dialogue meeting
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Collaboration between care manager, rehabilitation coordinator, and GP
Number of subjects: 25
Study: 33339541

Group type: EXPERIMENTAL
Intervention: Primary PCI during the pandemic (2020)
Number of subjects: 6609

Group type: COMPARATOR
Intervention: Door-to-balloon time and total ischemia times
Number of subjects: 6609

Group type: COMPARATOR
Intervention: Mortality during the pandemic
Number of subjects: 6609
Study: 33340064

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33340402

Group type: EXPERIMENTAL
Intervention: Serum progesterone levels <8.8 ng/ml on the day of ET
Number of subjects: 1205

Group type: COMPARATOR
Intervention: Serum progesterone levels ≥8.8 ng/ml on the day of ET
Number of subjects: 1205
Study: 33341314

Group type: EXPERIMENTAL
Intervention: Assessment of malnutrition according to GLIM criteria
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Assessment of nutritional status, particularly muscle status
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: 24-h urinary creatinine excretion rate (CER)
Number of subjects: 599
Study: 33341407

Group type: EXPERIMENTAL
Intervention: IV tobramycin (10 mg/kg/d, ≥10 days)
Number of subjects: 18
Study: 33341409

Group type: EXPERIMENTAL
Intervention: MVP cohort (mitral valve prolapse)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Non-MVP cohort
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Both MVP and non-MVP cohorts
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Elevated ECV
Number of subjects: 424
Study: 33341447

Group type: EXPERIMENTAL
Intervention: Bicalutamide
Number of subjects: 0
Study: 33341448

Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (serum levels <25 nmol/L)
Number of subjects: 1267

Group type: EXPERIMENTAL
Intervention: Sufficient vitamin D levels (serum levels >50 nmol/L)
Number of subjects: 1267

Group type: COMPARATOR
Intervention: Vitamin D levels (sufficient vs deficient) in resected stage I and II patients
Number of subjects: 1267

Group type: COMPARATOR
Intervention: Vitamin D levels in advanced PDAC
Number of subjects: 1267
Study: 33341870

Group type: EXPERIMENTAL
Intervention: Cord-blood IgG concentrations for serotype Ia
Number of subjects: 38233

Group type: EXPERIMENTAL
Intervention: Cord-blood IgG concentrations for serotype III
Number of subjects: 38233

Group type: EXPERIMENTAL
Intervention: Cord-blood IgG concentrations ≥1.04 µg/mL for serotype Ia
Number of subjects: 38233

Group type: EXPERIMENTAL
Intervention: Cord-blood IgG concentrations ≥1.53 µg/mL for serotype III
Number of subjects: 38233

Group type: EXPERIMENTAL
Intervention: Maternal sera IgG threshold ≥2.31 µg/mL for serotype Ia
Number of subjects: 38233

Group type: EXPERIMENTAL
Intervention: Maternal sera IgG threshold ≥3.41 µg/mL for serotype III
Number of subjects: 38233
Study: 33341883

Group type: EXPERIMENTAL
Intervention: Daily oral PrEP (emtricitabine 200 mg/tenofovir diphosphate 300 mg) administered for 12 weeks
Number of subjects: 40
Study: 33342078

Group type: EXPERIMENTAL
Intervention: Topical pain medication
Number of subjects: 153
Study: 33342228

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Thin-cap area measurement
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Macrophage index measurement
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Layered plaque assessment
Number of subjects: 84
Study: 33342342

Group type: EXPERIMENTAL
Intervention: PACER (Progressive Aerobic Cardiovascular Endurance Run)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: CMSP (CHAMPS Motor Skills Protocol)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Parental promotion of more screen time
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Higher parent concern for children's safety
Number of subjects: 144
Study: 33342437

Group type: EXPERIMENTAL
Intervention: Qualitative analysis of lived experiences of long Covid patients through interviews and focus groups.
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Suggested quality principles for long Covid services.
Number of subjects: 114
Study: 33342535

Group type: EXPERIMENTAL
Intervention: Laparoscopic unilateral oophorectomy for fertility preservation
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: FISH analysis of ovarian cells
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: IVG assay
Number of subjects: 1
Study: 33343285

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 33343425

Group type: EXPERIMENTAL
Intervention: Volunteer-Based Telehealth Program
Number of subjects: 0
Study: 33343483

Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Number of subjects: 0
Study: 33343498

Group type: EXPERIMENTAL
Intervention: Sensorimotor therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Motor therapy
Number of subjects: 0
Study: 33343722

Group type: EXPERIMENTAL
Intervention: FOLFOX4 plus hypofractionated tomotherapy
Number of subjects: 52
Study: 33343761

Group type: EXPERIMENTAL
Intervention: Mindfulness training delivered via mobile smoking cessation application (Craving to Quit, C2Q)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: NCI's QuitSTART smoking cessation application (NCI)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Written cessation materials (Materials)
Number of subjects: 146
Study: 33344227

Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg intravenously on days 1 and 15 with or without oral tadalafil
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg intravenously on days 1 and 15
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Nivolumab plus tadalafil
Number of subjects: 44
Study: 33344457

Group type: EXPERIMENTAL
Intervention: Radiomics analysis of multiparametric magnetic resonance imaging (MRI)
Number of subjects: 0
Study: 33344496

Group type: EXPERIMENTAL
Intervention: Excess intake of energy and saturated fat
Number of subjects: 0

Group type: COMPARATOR
Intervention: PNPLA3 genotype
Number of subjects: 0
Study: 33344717

Group type: EXPERIMENTAL
Intervention: Active transcutaneous cervical VNS (tcVNS), n = 13
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham device, n = 12
Number of subjects: 25
Study: 33344752

Group type: EXPERIMENTAL
Intervention: Intravenous allopregnanolone (2 mg, 4 mg, 6 mg, and 10 mg) administered once-per-week for 12 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo administered once-per-week for 12 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous allopregnanolone (various dosages)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous allopregnanolone
Number of subjects: 24
Study: 33344885

Group type: EXPERIMENTAL
Intervention: Subdural grid electrode implantation
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard treatment according to Brain Trauma Foundation guidelines
Number of subjects: 110
Study: 33345059

Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT) - 90 seconds to 12 minutes, 2-4 sessions/week for 16 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High Intensity Resistance Training (HIT-RT) - single set resistance training to muscular failure, 2-3 sessions/week for 16 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (details not provided)
Number of subjects: 0
Study: 33345095

Group type: EXPERIMENTAL
Intervention: Antioxidant-rich foods; specific dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group; specific intervention not available.
Number of subjects: 0
Study: 33345115

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33345336

Group type: EXPERIMENTAL
Intervention: Methadone therapy
Number of subjects: 93
Study: 33345620

Group type: EXPERIMENTAL
Intervention: Culturally targeted educational and communication skills intervention
Number of subjects: 74

Group type: COMPARATOR
Intervention: Telephone surveys and focus group interviews
Number of subjects: 74
Study: 33345877

Group type: EXPERIMENTAL
Intervention: Ratio of insulin-like growth factor-binding protein 4 to sex hormone-binding globulin
Number of subjects: 847
Study: 33345934

Group type: EXPERIMENTAL
Intervention: Personal gestational weight gain goal consistent with Institute of Medicine recommendations
Number of subjects: 6727

Group type: COMPARATOR
Intervention: Discussion of gestational weight gain goals with provider
Number of subjects: 6727
Study: 33345967

Group type: EXPERIMENTAL
Intervention: Invu system (wireless, wearable, self-administered device)
Number of subjects: 147
Study: 33346007

Group type: EXPERIMENTAL
Intervention: PPI therapy (pantoprazole 40 mg once daily for 4 weeks)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: PPI withdrawal in FD-stoppers
Number of subjects: 75

Group type: COMPARATOR
Intervention: PPI therapy in HVs
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Correlation of dyspeptic symptoms with eosinophils
Number of subjects: 75

Group type: COMPARATOR
Intervention: Increased eosinophils and permeability in HVs on PPIs
Number of subjects: 75
Study: 33346365

Group type: EXPERIMENTAL
Intervention: Corticoids (28.9%)
Number of subjects: 2798

Group type: EXPERIMENTAL
Intervention: Heart disease presence
Number of subjects: 2798

Group type: EXPERIMENTAL
Intervention: Heart disease patients
Number of subjects: 2798

Group type: EXPERIMENTAL
Intervention: Mortality in heart disease patients
Number of subjects: 2798
Study: 33346428

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs) prescribed in 28.3% of cases; 90.2% of patients with UGI bleeding received PPI.
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy for 6-12 months after elective PCI.
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: Patients with UGI bleeding and thrombotic events.
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: History of peptic ulcer disease.
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: Erosion of the upper gastrointestinal tract.
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: Heart failure (HF).
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: Abdominal aortic aneurysm (AAA).
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: Peripheral artery atherosclerosis (APA).
Number of subjects: 934
Study: 33346476

Group type: EXPERIMENTAL
Intervention: Patients with chronic coronary artery disease and diabetes mellitus
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: Obese patients (BMI ≥ 30 kg/m2)
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 1023
Study: 33346510

Group type: EXPERIMENTAL
Intervention: Indirect cold atmospheric plasma (CAP) treatment for 3 months
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Indirect cold atmospheric plasma (CAP) treatment for 6 months
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Investigator's assessment of indirect CAP treatment
Number of subjects: 14
Study: 33346740

Group type: EXPERIMENTAL
Intervention: Word2Vec convolutional neural network (CNN) MBR algorithms
Number of subjects: 14075

Group type: EXPERIMENTAL
Intervention: Word2Vec CNN MBR combined with rule-based reasoning (RBR)
Number of subjects: 14075
Study: 33346991

Group type: EXPERIMENTAL
Intervention: LVAD support
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: LVAD patients with thromboembolic events (TEs)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: LVAD implantation
Number of subjects: 43
Study: 33347326

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 0
Study: 33347327

Group type: EXPERIMENTAL
Intervention: Intervention details not available
Number of subjects: 0
Study: 33347373

Group type: EXPERIMENTAL
Intervention: Dilation velocity
Number of subjects: 0
Study: 33347495

Group type: EXPERIMENTAL
Intervention: Cetuximab treatment
Number of subjects: 493
Study: 33347618

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 1132
Study: 33347715

Group type: EXPERIMENTAL
Intervention: 225Ac-labeled CD33-targeting antibody
Number of subjects: 0

Group type: COMPARATOR
Intervention: Venetoclax
Number of subjects: 0
Study: 33347814

Group type: EXPERIMENTAL
Intervention: PARP inhibitors
Number of subjects: 9000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9000
Study: 33347946

Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF) applied topically for 2 minutes, repeated every 6 months
Number of subjects: 62
Study: 33348423

Group type: COMPARATOR
Intervention: Non-pharmacological treatment (modifying environmental stimulation)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Non-pharmacological treatment (feeding practices)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Non-pharmacological treatment (support of the maternal-infant dyad)
Number of subjects: 353
Study: 33348425

Group type: EXPERIMENTAL
Intervention: Nolix device
Number of subjects: 26
Study: 33348999

Group type: EXPERIMENTAL
Intervention: Statins (specific type, dosage, and duration not available)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (specific treatment or placebo not available)
Number of subjects: 0
Study: 33349123

Group type: EXPERIMENTAL
Intervention: CAR T cell therapy combined with oncolytic viruses (OVs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33350030

Group type: EXPERIMENTAL
Intervention: SomBP1 (SOMNOtouch NIBP device)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: SomBP2 (SOMNOtouch NIBP device)
Number of subjects: 51

Group type: COMPARATOR
Intervention: OscBP (validated oscillometric device)
Number of subjects: 51
Study: 33350181

Group type: EXPERIMENTAL
Intervention: Silica-calcium phosphate composite (SCPC) granules
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control ungrafted sockets
Number of subjects: 10
Study: 33350618

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 20% albumin at 3 mL/kg over 30 minutes
Number of subjects: 15
Study: 33350943

Group type: EXPERIMENTAL
Intervention: Client food bags HEI-2010 scores
Number of subjects: 575

Group type: COMPARATOR
Intervention: Pantry inventory HEI-2010 scores
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Client food bag whole-grains scores
Number of subjects: 575
Study: 33351103

Group type: EXPERIMENTAL
Intervention: α-1-antitrypsin (AAT) treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: MAGIC control group
Number of subjects: 30
Study: 33351137

Group type: EXPERIMENTAL
Intervention: Anti-ENO1 IgG2
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Anti-H2A IgG2
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Anti-ANXA1 IgG2
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Anti-dsDNA IgG2
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Proteinuria
Number of subjects: 221
Study: 33351179

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33351205

Group type: EXPERIMENTAL
Intervention: Follow-up samples of testosterone concentrations
Number of subjects: 400

Group type: COMPARATOR
Intervention: Baseline samples of testosterone concentrations
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) measurements
Number of subjects: 400
Study: 33351775

Group type: EXPERIMENTAL
Intervention: Home-use smell and taste test kit for daily self-assessments over 28 days
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Standardized smell and taste test
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Questionnaires to record recent changes in smell and taste ability
Number of subjects: 69
Study: 33352123

Group type: EXPERIMENTAL
Intervention: Scene construction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normalization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive processes
Number of subjects: 0
Study: 33352201

Group type: EXPERIMENTAL
Intervention: Copanlisib (60 mg) + Gemcitabine (1000 mg/m²)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Copanlisib + Gemcitabine
Number of subjects: 28
Study: 33352296

Group type: EXPERIMENTAL
Intervention: Direct acting antiviral therapy
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 85

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 85
Study: 33353741

Group type: EXPERIMENTAL
Intervention: Baveno VI criteria
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 33354492

Group type: EXPERIMENTAL
Intervention: Online training
Number of subjects: 78

Group type: COMPARATOR
Intervention: In-person training
Number of subjects: 78

Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 78
Study: 33354776

Group type: EXPERIMENTAL
Intervention: Icaritin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Icaritin in combination with checkpoint antibodies (α-PD-1)
Number of subjects: 0
Study: 33354862

Group type: EXPERIMENTAL
Intervention: BI 409306 50 mg twice daily for 52 weeks
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 33355229

Group type: EXPERIMENTAL
Intervention: ONCR-177
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 33355235

Group type: EXPERIMENTAL
Intervention: Mobile health readiness assessment via a 30-item questionnaire
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: Mobile health proficiency by age group
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: Mobile health proficiency by ethnicity and education
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: Employment status and mobile health proficiency
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: Home dialysis and mobile health proficiency
Number of subjects: 949
Study: 33355238

Group type: EXPERIMENTAL
Intervention: MK-4166 900 mg i.v. every 3 weeks as monotherapy
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: MK-4166 with pembrolizumab 200 mg i.v. every 3 weeks for ≤35 doses
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 113
Study: 33355273

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOACs) - dabigatran, rivaroxaban, apixaban
Number of subjects: 256546

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 256546
Study: 33355854

Group type: EXPERIMENTAL
Intervention: Turkish version of the Oxford Participation and Activities Questionnaire (Ox-PAQ)
Number of subjects: 290
Study: 33355907

Group type: EXPERIMENTAL
Intervention: ACO patients (n=101)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Non-ACO patients (n=295)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: ACO patients
Number of subjects: 396
Study: 33355914

Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg (DTG)-based regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose Efavirenz 400 mg (EFV400)-based regimen
Number of subjects: 0